Anaphylaxis Management: Epinephrine Dosing and Biphasic Reactions

Biphasic Reactions: Risk Factors and Observation Duration

Biphasic reactions (recurrence of symptoms after initial resolution without re-exposure) occur in 1-20% of anaphylaxis episodes, typically within 1-72 hours (median 8-10 hours)[3]. Risk factors for biphasic reactions include: severe initial presentation requiring multiple epinephrine doses, delayed initial epinephrine administration (greater than 60 minutes), wide pulse pressure on presentation, and unknown trigger. The 2024 guidelines recommend a minimum 4-hour observation period for mild-moderate anaphylaxis and 8-24 hours for severe anaphylaxis[5] with refractory hypotension, respiratory compromise, or risk factors for biphasic reactions.

Discharge Planning and Long-Term Management

All patients must be discharged with an epinephrine autoinjector prescription (two devices), a written anaphylaxis action plan, and referral to an allergist for trigger identification and possible immunotherapy. Patients with concurrent asthma are at higher risk for severe episodes. Prescribe a 2-3 day course of oral antihistamines and consider a short prednisone course for patients with significant mucosal edema. Counsel patients on the 1-20% risk of biphasic reactions and indications for re-presenting to the emergency department.

The Most Common Errors in Anaphylaxis Management

Despite the simplicity of the core algorithm — give epinephrine early, give it intramuscularly, repeat if needed — anaphylaxis management errors remain common and consequential. The most frequent error is delayed epinephrine administration: clinicians administer antihistamines, initiate IV access, or wait for a senior colleague rather than giving epinephrine first. Antihistamines treat hives, not anaphylaxis. The second most common error is using the wrong concentration — IV epinephrine at the IM concentration (1:1,000 instead of 1:10,000) can cause fatal arrhythmia. The third is inadequate observation: discharging a patient who responded to one dose of epinephrine after a short observation period misses the biphasic window. And the fourth — perhaps most impactful in the long term — is failing to prescribe epinephrine autoinjectors and arrange allergist follow-up at discharge. A patient who survives anaphylaxis but leaves the hospital without an autoinjector is set up for a potentially worse outcome at the next exposure.

Limitations and Ongoing Questions

The evidence base for anaphylaxis management is limited by the impossibility of conducting placebo-controlled trials of epinephrine for a life-threatening condition — the foundational role of epinephrine rests on decades of clinical experience and observational data rather than randomized controlled trials. The optimal observation duration remains debated, with the 4-hour minimum representing a pragmatic compromise between safety and emergency department throughput. Whether corticosteroids truly prevent biphasic reactions is unresolved, and a definitive trial is unlikely to be conducted given the large sample size that would be required. And the autoinjector landscape — with ongoing cost, availability, and dosing limitations — means that the most effective emergency treatment for anaphylaxis remains inconsistently accessible to the patients who need it most.

References

1. Epinephrine absorption in adults: intramuscular versus subcutaneous injection
2. Biphasic and protracted anaphylaxis systematic review
3. Biphasic and protracted anaphylaxis: systematic review of incidence and risk factors
4. Anaphylaxis practice parameters and WAO guidelines
5. Anaphylaxis observation duration guidelines
6. WAO anaphylaxis guidelines (tryptase criterion)